CROSSJECT (EPA:ALCJ) | WebDisclosure

PRESS RELEASE

published on 09/22/2025 at 07:30, 4 months 28 days ago

CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
CROSSJECT secures $11.3 million BARDA funding for ZEPIZURE® development towards FDA authorization. Advances include validation batches and facility audit completion

BARDA Funding Crossject FDA Authorization ZEPIZURE Development Emergency Auto-injectors
PRESS RELEASE

published on 09/22/2025 at 07:30, 4 months 28 days ago

CROSSJECT obtient un financement supplémentaire de la BARDA pour soutenir le développement et l'autorisation par la FDA de ZEPIZURE®
CROSSJECT obtient un financement supplémentaire de 11,3 millions de dollars de la BARDA pour le développement de ZEPIZURE® approuvé par la FDA

FDA Financement Crossject ZEPIZURE BARDA
BRIEF

published on 07/01/2025 at 07:35, 7 months 19 days ago

Change of liquidity contract for CROSSJECT

Liquidity Euronext Pharmaceutical Contract Crossject
BRIEF

published on 07/01/2025 at 07:35, 7 months 19 days ago

Changement de contrat de liquidité pour CROSSJECT

Contrat Euronext Liquidité Pharmaceutique Crossject
PRESS RELEASE

published on 07/01/2025 at 07:30, 7 months 19 days ago

CROSSJECT annonce la cessation et la mise en œuvre d’un nouveau contrat de liquidité
CROSSJECT annonce la cessation et la mise en œuvre d’un nouveau contrat de liquidité avec Rothschild Martin Maurel pour favoriser la liquidité des transactions. Détails du contrat et impacts sur le marché réglementé d'Euronext

Contrat De Liquidité Rothschild Martin Maurel Euronext Crossject ZENEO®
BRIEF

published on 06/24/2025 at 19:05, 7 months 26 days ago

CROSSJECT obtient une augmentation de capital de 5,7 millions d'euros

Augmentation De Capital Soumission À La FDA ZEPIZURE® Gemmes Venture Vatel Capital
BRIEF

published on 06/24/2025 at 19:05, 7 months 26 days ago

CROSSJECT Secures €5.7 Million in Capital Increase

Capital Increase FDA Submission ZEPIZURE® Gemmes Venture Vatel Capital
PRESS RELEASE

published on 06/24/2025 at 19:00, 7 months 26 days ago

CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
CROSSJECT successfully completes a capital increase of €5.7 million through preferential subscription rights, benefiting from new investor support and Gemmes Venture, to advance ZEPIZURE® development

Capital Increase Crossject ZEPIZURE® Gemmes Venture Vatel Capital
PRESS RELEASE

published on 06/24/2025 at 19:00, 7 months 26 days ago

CROSSJECT annonce le vif succès de son augmentation de capital portée à 5,7 millions d’euros après exercice intégral de la clause d’extension
CROSSJECT annonce le vif succès de son augmentation de capital à 5,7 millions d’euros après exercice intégral de la clause d’extension pour ZEPIZURE®

Financement Augmentation De Capital Pharmaceutique Crossject ZEPIZURE
BRIEF

published on 06/11/2025 at 07:35, 8 months 9 days ago

CROSSJECT advances in the development of ZEPIZURE® Junior for children

Epilepsy Pediatrics Crossject Auto-injector ZEPIZURE Junior

Published on 02/20/2026 at 18:30, 1 hour 40 minutes ago

Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 4 hours 25 minutes ago

Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 5 hours 40 minutes ago

Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 6 hours 2 minutes ago

Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 6 hours 10 minutes ago

Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors

View all ACCESSWIRE

Published on 02/20/2026 at 18:36, 1 hour 34 minutes ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 1 hour 39 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:23, 1 hour 47 minutes ago

POS-Transaction in Own Shares
Published on 02/20/2026 at 18:00, 2 hours 10 minutes ago

Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 2 hours 10 minutes ago

Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations

View all EQS

Published on 02/20/2026 at 19:29, 41 minutes ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 41 minutes ago

SFPI GROUP: bilan du contrat de liquidité S2 S025
Published on 02/20/2026 at 18:00, 2 hours 10 minutes ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 18:00, 2 hours 10 minutes ago

TERACT - Résiliation du contrat de liquidité
Published on 02/20/2026 at 17:35, 2 hours 35 minutes ago

CHIFFRE D'AFFAIRES 2025

View all LES ECHOS COMFI WIRE

News